Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention. - Seite 2

Dr. Zain Khalpey, the Director of the Khalpey AI Lab, stated, "Our team is dedicated to advancing the field of AI, with a focus on creating innovative healthcare solutions. We are proud to work with partners to achieve our goals and bring these solutions to the patient bedside. Our AI Lab is passionate about positively impacting healthcare outcomes. The partnership between Biogenysis and Contenta is a significant step forward in the fight against Alzheimer's disease. This includes identifying early biomarkers for use in delaying disease progression to benefit countless patients. We feel honored to contribute to Dr. Chandra's state-of-the-art AI platform, which has the potential to revolutionize various therapeutic approaches."

Dr. Gaurav Chandra, CEO of Biogenysis, Inc., said, "In Alzheimer's, the neurons in the brain responsible for memory, language, and thinking are damaged first. Even though these symptoms are new to the affected person, the changes in the brain that cause them are believed to start at least 20 years before the symptoms manifest. With this collaboration, we aim to find early biomarkers for Alzheimer's disease and discover new therapeutic targets to slow its progression."

The CEO of Enzolytics, Charles Cotropia, said: "With regard to the future use of Artificial Intelligence, we agree with experts who have said, ‘AI will change the world'. It is undeniable that AI will impact healthcare as well as all other technology areas. Biogenysis is at the forefront of applying AI to create new and improved health therapies. The Company has 4 pending International Patent Applications claiming significant discoveries derived from application of its AI Platform to produce new and effective therapies. Many more developments are planned including the patenting of each. Our partnering with Khalpey AI Lab and Contenta, Ltd. will accelerate the Company's objective to use AI to develop infectious disease therapeutics for improving health care around the world. This partnership and our planned business combination with Sagaliam Acquisition Corporation will provide the basis for achieving this objective."

Enzolytics, Inc. Overview

Enzolytics, Inc. is a drug development company committed to commercializing its proprietary monoclonal antibodies and proteins to treat debilitating infectious diseases.

Biogenysis, Inc., a subsidiary of Enzolytics, Inc., uses proprietary techniques to produce fully human monoclonal antibodies (mAbs) against infectious diseases. The technology is currently being employed to produce monoclonal antibody therapeutics for treating the CoronaVirus (SARS-CoV-2), HIV-1 and the Feline Leukemia Virus. The Company has also identified conserved epitopes on and has plans to produce mAbs targeting many other viruses, including H1N1 Influenza, HTLV1 & HTLV2, Leukemia Virus, Herpes Simplex I Virus, Respiratory Syncytial Virus (RSV), Smallpox Virus, Rabies, Influenza A, Influenza B, Ebola Virus, Epstein Barr Virus, and Monkey Pox Virus. The Company has also analyzed epitopes of animal viruses and plans to produce mAbs for treating these animal viruses.